Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects

Chemistry and Biology

Volumn 17, Issue 11, 2010, Pages 1256-1266

  Godlewski, Grzegorz ^a   Alapafuja, Shakiru O ^b   Bátkai, Sándor ^a   Nikas, Spyros P ^b   Cinar, Resat ^a   Offertáler, László ^a   Osei Hyiaman, Douglas ^a   Liu, Jie ^a   Mukhopadhyay, Bani ^a   Harvey White, Judith ^a   Tam, Joseph ^a   Pacak, Karel ^c   Blankman, Jacqueline L ^d   Cravatt, Benjamin F ^d   Makriyannis, Alexandros ^b   Kunos, George ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKANESULFONIC ACID; AM 3506; AMIDASE; AMIDE; ANANDAMIDE; ANTIHYPERTENSIVE AGENT; ARACHIDONIC ACID DERIVATIVE; CANNABINOID 1 RECEPTOR; ENZYME INHIBITOR; FATTY ACID AMIDASE; FATTY-ACID AMIDE HYDROLASE; PHENOL DERIVATIVE;

ANIMAL; ARTICLE; BRAIN; CHEMISTRY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HYPERTENSION; MALE; METABOLISM; MOUSE; MOUSE MUTANT; RAT;

ALKANESULFONATES; AMIDOHYDROLASES; ANIMALS; ANTIHYPERTENSIVE AGENTS; ARACHIDONIC ACIDS; BRAIN; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HYPERTENSION; MALE; MICE; MICE, KNOCKOUT; PHENOLS; POLYUNSATURATED ALKAMIDES; RATS; RECEPTOR, CANNABINOID, CB1;

MUS; RATTUS;

EID: 78649349136     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2010.08.013     Document Type: Article

References (44)

1. K. Ahn, D.S. Johnson, L.R. Fitzgerald, M. Liimatta, A. Arendse, T. Stevenson, E.T. Lund, R.A. Nugent, T.K. Nomanbhoy, and J.P. Alexander Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity Biochemistry 46 2007 13019 13030
2. K. Ahn, D.S. Johnson, M. Mileni, D. Beidler, J.Z. Long, M.K. McKinney, E. Weerapana, N. Sadagopan, M. Liimatta, and S.E. Smith Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain Chem. Biol. 16 2009 411 420
3. S. Batkai, P. Pacher, D. Osei-Hyiaman, S. Radaeva, J. Liu, J. Harvey-White, L. Offertaler, K. Mackie, M.A. Rudd, and R.D. Bukoski Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension Circulation 110 2004 1996 2002
4. D.T. Brozoski, C. Dean, F.A. Hopp, C.J. Hillard, and J.L. Seagard Differential endocannabinoid regulation of baroreflex-evoked sympathoinhibition in normotensive versus hypertensive rats Auton. Neurosci. 150 2009 82 93
5. K.P. Chiang, A.L. Gerber, J.C. Sipe, and B.F. Cravatt Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use Hum. Mol. Genet. 13 2004 2113 2119
6. B.F. Cravatt, D.K. Giang, S.P. Mayfield, D.L. Boger, R.A. Lerner, and N.B. Gilula Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides Nature 384 1996 83 87
7. B.F. Cravatt, K. Demarest, M.P. Patricelli, M.H. Bracey, D.K. Giang, B.R. Martin, and A.H. Lichtman Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase Proc. Natl. Acad. Sci. USA 98 2001 9371 9376
8. D.G. Deutsch, and S.A. Chin Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist Biochem. Pharmacol. 46 1993 791 796
9. D.G. Deutsch, S. Lin, W.A. Hill, K.L. Morse, D. Salehani, G. Arreaza, R.L. Omeir, and A. Makriyannis Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor Biochem. Biophys. Res. Commun. 231 1997 217 221
10. T.P. Dinh, D. Carpenter, F.M. Leslie, T.F. Freund, I. Katona, S.L. Sensi, S. Kathuria, and D. Piomelli Brain monoglyceride lipase participating in endocannabinoid inactivation Proc. Natl. Acad. Sci. USA 99 2002 10819 10824
11. E.K. Dziadulewicz, S.J. Bevan, C.T. Brain, P.R. Coote, A.J. Culshaw, A.J. Davis, L.J. Edwards, A.J. Fisher, A.J. Fox, and C. Gentry Naphthalen-1-yl-(4- pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration J. Med. Chem. 50 2007 3851 3856
12. G. Eisenhofer, D.S. Goldstein, R. Stull, H.R. Keiser, T. Sunderland, D.L. Murphy, and I.J. Kopin Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase Clin. Chem. 32 1986 2030 2033
13. D. Fegley, S. Kathuria, R. Mercier, C. Li, A. Goutopoulos, A. Makriyannis, and D. Piomelli Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172 Proc. Natl. Acad. Sci. USA 101 2004 8756 8761
14. A. Fontana, V. Di Marzo, H. Cadas, and D. Piomelli Analysis of anandamide, an endogenous cannabinoid substance, and of other natural N-acylethanolamines Prostaglandins Leukot. Essent. Fatty Acids 53 1995 301 308
15. C.J. Fowler, M. Borjesson, and G. Tiger Differences in the pharmacological properties of rat and chicken brain fatty acid amidohydrolase Br. J. Pharmacol. 131 2000 498 504
16. C. Ge, R. Garcia, and M.B. Anand-Srivastava Enhanced expression of Gialpha protein and adenylyl cyclase signaling in aortas from 1 kidney 1 clip hypertensive rats Can. J. Physiol. Pharmacol. 84 2006 739 746
17. P.G. Guyenet The sympathetic control of blood pressure Nat. Rev. Neurosci. 7 2006 335 346
18. A.C. Howlett Cannabinoid receptor signaling Handb. Exp. Pharmacol. 2005 53 79
19. D.R. Janero, S.K. Vadivel, and A. Makriyannis Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategies Int. Rev. Psychiatry 21 2009 122 133
20. Z. Justinova, R.A. Mangieri, M. Bortolato, S.I. Chefer, A.G. Mukhin, J.R. Clapper, A.R. King, G.H. Redhi, S. Yasar, and D. Piomelli Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates Biol. Psychiatry 64 2008 930 937
21. D.A. Kass, W.L. Maughan, Z.M. Guo, A. Kono, K. Sunagawa, and K. Sagawa Comparative influence of load versus inotropic states on indexes of ventricular contractility: experimental and theoretical analysis based on pressure-volume relationships Circulation 76 1987 1422 1436
22. S. Kathuria, S. Gaetani, D. Fegley, F. Valino, A. Duranti, A. Tontini, M. Mor, G. Tarzia, G. La Rana, and A. Calignano Modulation of anxiety through blockade of anandamide hydrolysis Nat. Med. 9 2003 76 81
23. C.K. Kost, W.A. Herzer, P.J. Li, and E.K. Jackson Pertussis toxin-sensitive G-proteins and regulation of blood pressure in the spontaneously hypertensive rat Clin. Exp. Pharmacol. Physiol. 26 1999 449 455
24. G. Kunos The hepatic alpha1-adrenoceptor Trends Pharmacol. Sci. 5 1984 380 383
25. K.D. Lake, D.R. Compton, K. Varga, B.R. Martin, and G. Kunos Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors J. Pharmacol. Exp. Ther. 281 1997 1030 1037
26. D. Leung, C. Hardouin, D.L. Boger, and B.F. Cravatt Discovering potent and selective reversible inhibitors of enzymes in complex proteomes Nat. Biotechnol. 21 2003 687 691
27. D. Lu, V.K. Vemuri, R.I. Duclos Jr., and A. Makriyannis The cannabinergic system as a target for anti-inflammatory therapies Curr. Top. Med. Chem. 6 2006 1401 1426
28. J. Marcil, J. de Champlain, and M.B. Anand-Srivastava Overexpression of Gi-proteins precedes the development of DOCA-salt-induced hypertension: relationship with adenylyl cyclase Cardiovasc. Res. 39 1998 492 505
29. J. Marcil, C. Thibault, and M.B. Anand-Srivastava Enhanced expression of Gi-protein precedes the development of blood pressure in spontaneously hypertensive rats J. Mol. Cell. Cardiol. 29 1997 1009 1022
30. W.R. Marrs, J.L. Blankman, E.A. Horne, A. Thomazeau, Y.H. Lin, J. Coy, A.L. Bodor, G.G. Muccioli, S.S. Hu, and G. Woodruff The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors Nat. Neurosci. 13 2010 951 957
31. F.A. Moreira, N. Kaiser, K. Monory, and B. Lutz Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors Neuropharmacology 54 2008 141 150
32. N. Niederhoffer, K. Schmid, and B. Szabo The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression Naunyn Schmiedebergs Arch. Pharmacol. 367 2003 434 443
33. D. Osei-Hyiaman, M. DePetrillo, P. Pacher, J. Liu, S. Radaeva, S. Batkai, J. Harvey-White, K. Mackie, L. Offertaler, and L. Wang Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity J. Clin. Invest. 115 2005 1298 1305
34. D. Osei-Hyiaman, J. Liu, L. Zhou, G. Godlewski, J. Harvey-White, W.I. Jeong, S. Batkai, G. Marsicano, B. Lutz, and C. Buettner Hepatic CB(1) receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice J. Clin. Invest. 118 2008 3160 3169
35. P. Pacher, S. Batkai, D. Osei-Hyiaman, L. Offertaler, J. Liu, J. Harvey-White, A. Brassai, Z. Jarai, B.F. Cravatt, and G. Kunos Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase Am. J. Physiol. Heart Circ. Physiol. 289 2005 H533 H541
36. P. Pacher, S. Batkai, and G. Kunos The endocannabinoid system as an emerging target of pharmacotherapy Pharmacol. Rev. 58 2006 389 462
37. P. Pacher, T. Nagayama, P. Mukhopadhyay, S. Batkai, and D.A. Kass Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats Nat. Protoc. 3 2008 1422 1434
38. R. Sarzani, M. Bordicchia, F. Salvi, G. Cola, E. Franchi, I. Battistoni, L. Mancinelli, A. Giovagnoli, P. Dessi-Fulgheri, and A. Rappelli A human fatty acid amide hydrolase (FAAH) functional gene variant is associated with lower blood pressure in young males Am. J. Hypertens. 21 2008 960 963
39. A.M. Schreihofer, D.A. Mandel, S.C. Mobley, and D.W. Stepp Impairment of sympathetic baroreceptor reflexes in obese Zucker rats Am. J. Physiol. Heart Circ. Physiol. 293 2007 H2543 H2549
40. J.L. Seagard, C. Dean, S. Patel, D.J. Rademacher, F.A. Hopp, W.T. Schmeling, and C.J. Hillard Anandamide content and interaction of endocannabinoid/GABA modulatory effects in the NTS on baroreflex-evoked sympathoinhibition Am. J. Physiol. Heart Circ. Physiol. 286 2004 H992 H1000
41. M. Seierstad, and J.G. Breitenbucher Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors J. Med. Chem. 51 2008 7327 7343
42. J. Tam, V.K. Vemuri, J. Liu, S. Batkai, B. Mukhopadhyay, G. Godlewski, D. Osei-Hyiaman, S. Ohnuma, S.V. Ambudkar, and J. Pickel Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity J. Clin. Invest. 120 2010 2953 2966
43. C. Tourino, F. Oveisi, J. Lockney, D. Piomelli, and R. Maldonado FAAH deficiency promotes energy storage and enhances the motivation for food Int. J. Obes. (Lond.) 34 2010 557 568
44. K. Varga, K.D. Lake, D. Huangfu, P.G. Guyenet, and G. Kunos Mechanism of the hypotensive action of anandamide in anesthetized rats Hypertension 28 1996 682 686